{"id":1182939,"date":"2026-09-02T18:50:20","date_gmt":"2026-09-02T18:50:20","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/1182939\/"},"modified":"2026-09-02T18:50:20","modified_gmt":"2026-09-02T18:50:20","slug":"surge-in-unapproved-glp-1-drugs-alarming-poison-control-safe-medicine-advocates-nbc-bay-area","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/1182939\/","title":{"rendered":"Surge in unapproved GLP-1 drugs alarming poison control, safe medicine advocates \u2013 NBC Bay Area"},"content":{"rendered":"

Compounded GLP-1 medications are mixed versions of the popular name brand weight loss drugs like Ozempic. They were initially created to address a drug shortage or an individual\u2019s unique medical need.<\/p>\n

While the shortage of GLP-1 medications is over, safe medicine advocates say these compounded versions are being mass produced and flooding the market.<\/p>\n

According to the FDA, unapproved GLP-1 medications can be riskier for patients, compared to approved drugs, because they don\u2019t undergo the same federal review for safety, effectiveness, and quality before they are marketed.<\/p>\n

The agency has publicly warned<\/a> about telehealth companies making false claims such as compounded drugs being the same as FDA-approved drugs. The FDA says patients should look out for significant discounts that seem too goo to be true, a lack of instruction, and a lack of screening by a licensed doctor.<\/p>\n

\u201cI was rushed to the emergency room.\u201d<\/strong><\/p>\n

Shawn Rose said when his insurance denied him coverage of a GLP-1 weight loss prescription in January, his primary doctor suggested telehealth, a virtual way to receive medical care.<\/p>\n

Living in Chicago, Illinois at the time, Rose downloaded Mochi Health\u2019s app. He paid about a couple hundred dollars a month to the San Francisco-based telehealth start-up company and began receiving shipments of compounded semaglutide, which is the active ingredient in other approved medications like Ozempic.<\/p>\n

When asked about the price difference, Rose said it was substantial.<\/p>\n

\u201cAbout a 75% saving based on what you would get at a doctor\u2019s office,\u201d he said. \u201cThe first vial seemed to go okay. They upped me dose\u2026then within about an hour to an hour and 15 minutes, I was rushed to the emergency room.\u201d<\/p>\n

Rose provided the Investigative Unit medical documents showing he went to the hospital multiple times. On TikTok, he documented his journey when he was admitted. He described not being able to hold down any food or water.<\/p>\n

\"<\/p>\n

Shawn Rose showing one of the vials he says he received from Mochi Health.<\/p>\n

\u201cI got so sick and there was a part of me that just thought I was going to die from it,\u201d Rose said.<\/p>\n

Rose said Illinois state regulators are looking into his case and his complaint against a Mochi nurse . When he sent her a long message in the Mochi Health app saying he was hospitalized, she appears to simply respond, \u201cI\u2019m sorry to hear that Shawn. Good luck to you.\u201d<\/p>\n

Rose said investigators were also concern about vials he received from Mochi Health with no labels.<\/p>\n

\u201cI don\u2019t know what I\u2019m taking. I have no idea,\u201d he said while holding up one of the vials.<\/p>\n

\"<\/p>\n

Photo provided by Shawn Rose.<\/p>\n

Telehealth companies advertising compounded GLP-1s<\/strong><\/p>\n

In June, the NBC Bay Area Investigative Unit reported on Mochi Health<\/a> and the closure of a pharmacy is used in Washington after state investigators there found the pharmacy allowed and even directed untrained pharmacy assistants to compound GLP-1 drugs.<\/p>\n

Regulators also found unlicensed workers processing prescriptions, expired medications about to be sent to patients, and other alarming violations.<\/p>\n

The Investigative Unit called the pharmacy and Mochi Health several times about these issues but neither responded.<\/p>\n

At a health conference in San Francisco earlier this year, Mochi Health\u2019s CEO Myra Ahmad<\/a> didn\u2019t want to answer our team\u2019s questions in-person.<\/p>\n

WATCH THE INVESTIGATIVE UNIT’S REPORT ON MOCHI HEALTH AND AEQUITA PHARMACY<\/a><\/strong><\/p>\n

\u201cThere\u2019s rarely any consequence for the harm onto patients that\u2019s been done by the telehealth company,\u201d Shabbir Imber Safdar said.<\/p>\n

Safdar is a certified fraud examiner and the executive director of the Partnership for Safe Medicines. He said the problems with Mochi Health point to a larger issue of telehealth companies mass marketing compounded weight loss drugs. Even though the drugs are unapproved, the supply has reached its highest volume in two decades creating what he sees as an industry-wide problem.<\/p>\n

\"<\/p>\n

Shabbier Imber Safdar, Executive Director of the Partnership for Safe Medicines.<\/p>\n

\u201cThey\u2019re just doing it as a money grab,\u201d he said. \u201cWe\u2019re very concerned because these medicines are not made under the same safety regulation as the FDA approved drugs. They\u2019re made from unnecessary medical reasons and they\u2019re often just less safe.\u201d<\/p>\n

Since last year, the Partnership for Safe Medicines has tracked 50 actions by state boards of pharmacy against compounders operating unsafely. Those actions include probation and revoking licenses. They\u2019ve also tracked 160 letters from the FDA to telehealth companies and compounders warning them about deceptive marketing.<\/p>\n

Concern of a lack of enforcement<\/strong><\/p>\n

\u201cBut the warning letters are only the start of the conversation about enforcement. They aren\u2019t taking it to the next level,\u201d Safdar said. \u201cYou\u2019re not seeing enough of these get referred to the Department of Justice. You\u2019re not seeing telehealth companies and compounders have their product recalled because they were deceptively sold.\u201d<\/p>\n

In an email to our Investigative Unit, the FDA said it \u201cwill continue to take action, where appropriate, to protect public health.\u201d<\/p>\n

\"<\/p>\n

The American Telemedicine Association said this is \u201cnot a telehealth issue, it\u2019s a bad actor issue\u2026[and] and subset of bad actors shouldn\u2019t be used to cast doubt on telehealth as a delivery model.\u201d<\/p>\n

Safdar said the FDA still needs to do more to hold the industry accountable.<\/p>\n

\u201cThat industry is endangering patients, and they need to up their game,\u201d he said.<\/p>\n","protected":false},"excerpt":{"rendered":"Compounded GLP-1 medications are mixed versions of the popular name brand weight loss drugs like Ozempic. They were…\n","protected":false},"author":2,"featured_media":1182940,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[4315],"tags":[557,105,4326,16,15],"class_list":["post-1182939","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-california","tag-health","tag-medication","tag-uk","tag-united-kingdom"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/117202954356925333","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/1182939","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=1182939"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/1182939\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/1182940"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=1182939"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=1182939"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=1182939"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}